Chandra Bhagat Pharma Secures BSE Approval for Preferential Warrant Issue

6.6 million convertible warrants to be issued at a minimum floor price of Rs 44 per share.

Reader Takeaway: Approval clears a key regulatory hurdle for capital infusion, though strict trading restrictions apply to allottees.

What just happened

Chandra Bhagat Pharma Ltd has received in-principle approval from the BSE to issue 6.6 million convertible warrants. Each warrant is convertible into one equity share of face value Rs 10. The company has set a floor price of Rs 44 per share for this preferential issue, which targets both promoter and non-promoter groups.

Why this matters

This approval is a critical regulatory milestone for the company's proposed capital-raising exercise. The funds generated from the conversion of these warrants are expected to provide liquidity and support the company's growth initiatives. For shareholders, this represents a formal step toward expanding the company’s equity base.

Regulatory Compliance and Conditions

The BSE approval mandates strict adherence to the Companies Act, 2013, and SEBI’s ICDR regulations. Key conditions include:

• Prohibiting allottees from engaging in intra-day trading or selling company shares before the formal allotment date.
• Requiring the company to collect written undertakings from allottees regarding these trading restrictions.
• Ensuring that listing applications are filed within 20 days post-allotment as per SEBI guidelines.

Risks to watch

The BSE retains the right to revoke this approval if it determines that any information provided by the company is misleading or incorrect. Investors should monitor for any potential regulatory non-compliance during the allotment process, as failure to meet listing formalities could lead to penalties or delays in the trading of these shares.

What to track next

Investors should monitor the subsequent announcement regarding the actual allotment date and the final subscription status from the identified allottees.